Alfadil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfadil

Property Description
Active ingredient Doxazosin (typically as the mesylate salt)
Form Oral tablet or extended-release tablet
Pharmacological class Selective Alpha-1-Adrenergic Blocker
General purpose Reducing vascular resistance and muscular tension
Origin Synthetic organic compound (quinazoline derivative)

Doxazosin: The Defining Compound in Alfadil

Alfadil is a prescription pharmaceutical whose active ingredient is Doxazosin, a compound classified as a Selective Alpha-1-Adrenergic Blocker. This medication is a single active ingredient product, most often administered using the stable salt Doxazosin mesylate. Doxazosin is a synthetic organic compound belonging to the quinazoline chemical class, engineered for systemic use via oral administration. The identity of the drug is therefore established by its specific quinazoline structure and its precise inhibitory action on targeted receptors, recognized for its effect in relaxing smooth muscle tissues.

What Type of Medicine is a Selective Alpha-1 Blocker?

A Selective Alpha-1-Adrenergic Blocker is a drug designed to modulate responses within the body’s involuntary nervous system by inducing smooth muscle relaxation in precise anatomical locations. This pharmacological class operates by competitively inhibiting alpha-1 receptors, which are signaling points on smooth muscle cells responsible for triggering contraction. The functional consequence of this receptor blockade is the promotion of vasodilation, the widening of blood vessels, as well as the relaxation of muscular tissue in certain organs. This mechanism defines the drug's overarching purpose in providing therapeutic relief from elevated pressures and muscular resistance within the circulatory and urinary systems.

Physical Forms of Alfadil: Tablet vs. Extended Release

Alfadil is primarily available in two key dosage forms: a conventional tablet and an extended-release tablet, both intended for oral intake. While the active substance Doxazosin remains identical, the forms differ in how they deliver the compound systemically. The extended-release version is designed to sustain the systemic action of Doxazosin over a longer duration by utilizing a controlled release mechanism. This represents a key differentiating feature, allowing for a steady, sustained presence of the active substance throughout the day, which contrasts with the absorption characteristics of the standard tablet formulation.

Regulatory References

  1. WHO
  2. DailyMed page for Doxazosin

What side effects are possible with Alfadil?

Possible Side Effects and Safety Information

The official safety documentation for Alfadil (Doxazosin) outlines adverse reactions based on their classification frequency, primarily affecting the nervous and cardiovascular systems. The most Common effects, reported in up to 1 in 10 patients, include dizziness, headache, somnolence (drowsiness), fatigue, and postural hypotension (dizziness upon standing).

Serious Adverse Reactions and Systemic Effects

Adverse reactions classified as Uncommon or Very Rare in regulatory documents include systemic issues and clinically significant events. Serious effects documented in labels include Syncope (loss of consciousness), cerebrovascular accident, and myocardial infarction. Very rare events include Priapism (painful, persistent erection) and hepatobiliary disorders such as Jaundice or Hepatitis. The condition Intraoperative Floppy Iris Syndrome (IFIS) is a reported safety concern associated with the alpha-1 blocker class during cataract surgery.

Time-Sensitive Safety Patterns and Restrictions

The risk of postural hypotension and syncope is explicitly documented as highest during the initiation of therapy or immediately following a dose increase. Use is generally not recommended in patients with a history of orthostatic hypotension or those with severe hepatic impairment due to lack of experience. Caution is also advised when administering the medicine to patients with certain pre-existing acute cardiac conditions. For the treatment of BPH, official regulatory texts require that prostate carcinoma be ruled out prior to commencing therapy.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documents define overdose of Alfadil (Doxazosin) as an acute event dominated by an exaggerated pharmacological action, primarily resulting in profound hypotension (severely low blood pressure). Other documented manifestations include drowsiness and changes in heart rate.

Documented Manifestations and Serious Outcomes

Primary Regulatory Concern Potential Severe Outcome
Profound hypotension Loss of consciousness (syncope)
Changes in heart rate Significant hemodynamic instability

Emergency Actions Mandated by Regulators

In the event of a known or suspected overdose, regulatory authorities mandate immediate action. You must seek emergency medical attention immediately, or contact a Poison Control Center. Emergency services should be called immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management and Antidote Status

The management of Doxazosin overdose is symptomatic and supportive, as no specific antidote is known. Officially described procedures include close monitoring of vital signs, measures to correct hypotension, and efforts to remove unabsorbed Doxazosin from the gastrointestinal tract.

Therapeutic Uses of Alfadil

What Alfadil Treats: Main Uses and Benefits

The therapeutic application of Alfadil (Doxazosin) is centered on managing conditions that involve heightened physiological activity, primarily in the circulatory and urinary systems, which contributes to easing the overall symptom load and supporting functional stability in clinical settings.

Management of Essential Hypertension and Vascular Risk

Alfadil is commonly used to help with the management of Essential Hypertension (high blood pressure), a condition characterized by periods of heightened systemic pressure that can create noticeable physiological strain. The compound is considered relevant for managing chronic high blood pressure and symptomatic Benign Prostatic Hyperplasia (BPH). The key therapeutic benefit helps support the reduction of blood pressure, which assists with maintaining functional stability and helps support the patient in managing long-term cardiovascular burden, helping to ease risks associated with chronic hypertension.

Relief of Symptomatic Benign Prostatic Hyperplasia (BPH)

This medication is relevant in addressing Lower Urinary Tract Symptoms (LUTS) associated with an enlarged prostate. It is used when symptom clusters like urinary frequency, urgency, weak stream, or nighttime waking (nocturia) interfere with daily functioning and comfort. The therapeutic use may assist with easing urinary outflow obstruction. This generally provides supportive relief, which may contribute to improved day-to-day comfort and assists with maintaining a sense of stability during periods of heightened symptoms.

Quick Fact: Relief for LUTS

Alfadil is commonly used to help with managing symptom clusters related to urinary frequency, urgency, and weak stream, which may assist with reducing the symptoms related to nocturnal waking (nocturia) in men with BPH.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Alfadil (Doxazosin) is officially approved for use in adult patients for the treatment of Essential Hypertension and Symptomatic Benign Prostatic Hyperplasia (BPH). Use in pediatric patients is not recommended, as the safety and efficacy of the medicine are not established in this age group.

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to doxazosin, other quinazolines, or any component of the formulation. Patients with pre-existing clinically significant hypotension or a documented history of orthostatic hypotension are also excluded from using this medicine.

For the treatment of BPH, additional restrictions apply. Alfadil is contraindicated in BPH patients with certain concomitant conditions, including upper urinary tract obstruction, chronic bladder infection, or co-existing cardiac issues such as specific aortic or mitral valve disorders. Regarding reproductive status, use is generally not recommended for women during pregnancy or lactation, as Doxazosin is known to be excreted in breast milk. Caution and potential restriction are also advised for patients with severe hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Alfadil

Alfadil's interaction profile is primarily determined by its potential for additive blood pressure effects and its hepatic metabolism via the CYP3A4 enzyme. Regulatory documentation classifies these clinically significant interactions as requiring caution.

Interaction Category Interacting Agents and Official Description
Pharmacodynamic Effects Co-administration with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) may result in additive blood pressure lowering effects and the risk of symptomatic hypotension. The blood pressure-lowering activity of other antihypertensives and vasodilating agents is also potentiated by Alfadil.
Metabolic (PK) Effects Strong CYP3A4 Inhibitors (such as Ketoconazole, Itraconazole, and certain antivirals) are expected to increase systemic exposure to Alfadil. This is due to the active substance being primarily cleared via the CYP3A4 pathway in the liver.

The official profile notes that Alcohol (Ethanol) consumption is documented to intensify the drug's blood pressure-lowering effect. Furthermore, Grapefruit Juice may elevate plasma concentrations by inhibiting the CYP3A4 enzyme. For specific populations, regulatory data indicates that Hepatic Impairment can lead to reduced clearance and an increase in systemic exposure of the drug, requiring particular caution in this context. No mandatory timing separation rules are documented for co-administration.

Mechanism of Action

How Alfadil Works

Alfadil (Doxazosin) works by competitively blocking a specific signaling point on certain muscle cells. Doxazosin's long half-life supports a sustained receptor blockade.


Molecular Target: Alpha-1 Adrenergic Receptor Blockade

Doxazosin acts as a highly selective antagonist to the Alpha-1 (alpha1) Adrenergic Receptors found on smooth muscle. This action prevents the activating signal from the sympathetic nervous system (via Norepinephrine) from binding to the receptor, thereby inhibiting the Gq-protein signaling cascade. This block is the first step in a sequence that results in smooth muscle relaxation in alpha1-rich tissues (vessels and urogenital tract).


Systemic Effect: Influence of Vascular Tone and Resistance

By inhibiting the contractile signal within blood vessel walls, the drug promotes vasodilation (vessel widening). This reduces the Systemic Vascular Resistance (SVR), which reduces the load against which the heart works. This same mechanism alters muscular tension in the urogenital smooth muscle, decreasing resistance in that tract. These two primary physiological consequences are central to the drug's overall effect profile.

Dosage and Administration Information

Administration Map: Dosing Guidelines

Alfadil (doxazosin) is administered via the oral route as a once-daily regimen. The available forms include an immediate-release tablet and an extended-release tablet. Administration parameters include the starting dose, frequency, dose adjustments, and tablet handling.


Dosing Rules and Titration

Indication Initial Dose (Once Daily) Titration Schedule Maximum Dose (Once Daily)
Hypertension (IR only) 1 mg 1- to 2-week intervals 16 mg
BPH (IR) 1 mg 1- to 2-week intervals 8 mg
BPH (ER) 4 mg 3- to 4-week intervals 8 mg

The immediate-release (IR) tablet may be taken with or without food, whereas the extended-release (ER) form is typically administered with breakfast. Dosing for both forms begins at the lowest amount and is increased gradually over specified time intervals to reach an individual maintenance amount.


Special Administration Conditions

The extended-release tablet must be swallowed whole with water and must not be chewed, divided, or crushed. The integrity of this form is essential for its proper function. If therapy is discontinued for several days, standard practice involves re-initiating treatment using the initial lowest dose and following the full titration schedule again. Patients with hepatic impairment typically receive the medicine with particular caution. Use in the pediatric population (under 18 years) is generally not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alfadil

Evidence for use in Benign Prostatic Hyperplasia (BPH)

This section will summarize the research findings from clinical trials and studies that specifically investigated the use of Alfadil in research exploring the signs and symptoms associated with an enlarged prostate.

Alfadil was studied in populations with BPH, a condition marked by functional limitations and urinary symptoms. Research examined short-term randomized, placebo-controlled trials (RCTs). Studies reported measurements of difference in symptom severity between participants receiving Alfadil and those receiving a placebo, and the research highlights changes measured during the short-term study periods. What remains uncertain is the long-term pattern of observed measurements. Follow-up durations were limited, meaning there is limited information for long-term outcomes.

Evidence for use in Hypertension (High Blood Pressure)

This section will outline what studies, primarily randomized trials, have been conducted to evaluate the effects of Alfadil on blood pressure measurements in adults with high blood pressure.

Alfadil was also evaluated in adults with high blood pressure, a condition associated with systemic or functional imbalance. Research examined short- to medium-term clinical trials. Some trials reported measurements where blood pressure readings appeared to be lower in the groups studied with Alfadil compared to the control groups. Research indicates that Alfadil was observed in studies exploring short-term changes in blood pressure. However, certainty remains low regarding the sustained patterns of these measured changes over many years, as follow-up durations were limited.

What is Still Uncertain About Alfadil

Multiple research limitation frames apply to the current evidence landscape for Alfadil. The certainty remains low for several aspects of its use, as follow-up durations were limited across most trials. This means there is limited information for long-term outcomes and the durability of observed patterns. In addition, findings were mixed across some studies, and comparative evidence is lacking; specifically, head-to-head comparisons against all relevant established interventions are not fully available or consistent. The evidence highlights what is known—and what is still uncertain—about Alfadil.

Frequently Asked Questions (FAQ)

Common questions about Alfadil (FAQ)


Q: What happens if I stop taking Alfadil suddenly?

Official guidance documents address the process for restarting treatment after an interruption of therapy. If use is discontinued for several days, regulatory information recommends re-initiating treatment using the initial lowest dose and following the full titration schedule again. Official guidance emphasizes consulting with a healthcare professional regarding any planned changes to determine the proper management plan.


Q: How quickly can someone expect Alfadil to start working?

Studies on Alfadil (doxazosin) show that its effects can begin relatively quickly after dosing. For blood pressure management, maximum reductions in blood pressure were observed a few hours after the medicine was taken in studies. For symptoms related to benign prostatic hyperplasia (BPH), improvement is reported to often be observed within one to two weeks of beginning therapy.


Q: Is Alfadil a type of beta-blocker?

No, Alfadil is not classified as a beta-blocker. It belongs to a different class of medicines known as alpha-1 adrenergic blockers (or alpha-antagonists). This means the medicine works by targeting different specific receptors in the body than those targeted by beta-blockers.


Q: Do older adults need a different dosage of Alfadil?

Regulatory data indicates that the medicine’s effects are generally similar in younger and older adults. Official documents indicate that lower initial doses and gradual adjustments are sometimes used in this population due to reported sensitivity to the medicine’s blood pressure-lowering effects.


Q: Can women who are pregnant or breastfeeding use Alfadil?

Official regulatory documents note that there is insufficient data to confirm the safety of using Alfadil while pregnant. Similarly, the safety of using the medicine during breastfeeding has not been definitively established. Decisions regarding the use of this medicine during pregnancy or while breastfeeding are managed by a healthcare professional.


Q: Is Alfadil a controlled substance?

Alfadil (doxazosin) is consistently regulated as a prescription-only medicine. It is not classified as a federally controlled substance by major regulatory agencies.


Q: Does Alfadil show up on standard drug tests?

Alfadil (doxazosin) is generally not included in standard, routine drug testing panels. It may be detected in specialized screenings designed specifically for antihypertensive or cardiovascular medications.


Q: Can Alfadil be taken on an empty stomach?

The immediate-release form of Alfadil may be taken either with food or without food, based on official prescribing information. The extended-release form, however, is typically advised to be taken with food, often with breakfast, to ensure proper function.


Q: Is Alfadil a blood thinner?

Alfadil is classified as an alpha-1-adrenergic receptor antagonist, and its primary function is to block specific receptors to lower blood pressure. It is not classified as a blood thinner, which are medicines that specifically affect blood clotting. However, research has noted an observed effect on inhibiting platelet aggregation.


Q: Why does Alfadil sometimes cause headaches?

Headache is listed in regulatory documents as a common adverse reaction for Alfadil. While the medicine causes vasodilation (widening of blood vessels), official regulatory sources list headache as a common side effect but do not provide a specific physiological explanation for its occurrence.


Q: Does the effectiveness of Alfadil decrease over time?

Official regulatory documents indicate that, unlike some other alpha-blocking medicines, no tolerance to the drug's effects has been observed during long-term treatment with Alfadil (doxazosin) in clinical settings.


Q: Are there any foods or drinks to avoid while using Alfadil?

Regulatory information notes a potential for interaction with both alcohol and grapefruit juice. Alcohol consumption is documented to intensify the medicine's blood pressure-lowering effect. Grapefruit juice may increase the amount of Alfadil in the body by affecting a specific liver enzyme.


Q: What age group is Alfadil generally prescribed for?

Alfadil is primarily intended for use in adults aged 18 years and over. Official prescribing information states that the use of this medicine in the pediatric population (under 18) is generally not recommended.


Q: Is Alfadil known to interact with herbal supplements?

Official guidance often recommends caution regarding the use of herbal supplements, as sufficient testing data to confirm safety with Alfadil is frequently unavailable. Interactions may occur, particularly with supplements that can affect the same liver enzyme (CYP3A4) used to process Alfadil.


Q: What should I do if a side effect of Alfadil becomes bothersome?

Patients are instructed by official patient information to report any suspected adverse reactions to their healthcare provider. For specific, serious effects (such as a painful, persistent erection or fainting), immediate emergency medical attention is necessary.


Q: What if I forget to take a dose of Alfadil?

Official patient information often describes a management plan for a missed dose, typically advising patients to take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the instruction is to skip the missed dose and only take the next dose at the regular time, without taking double or extra doses.


Q: Does Alfadil affect a person's ability to drive?

Regulatory documents advise that Alfadil may impact reaction time or judgment due to potential side effects like dizziness or drowsiness. Patients should be aware that official warnings advise avoiding driving or operating complex machinery until they are familiar with how the medicine affects them, particularly after starting the drug or after a dose increase.


Q: Is it possible to be allergic to Alfadil?

Yes, official regulatory documents list a contraindication for patients with known hypersensitivity (allergy) to Alfadil (doxazosin), other quinazoline medicines, or any of the inactive ingredients found in the tablets.


Q: What happens in the body when Alfadil starts working?

When Alfadil begins its action, it blocks specific alpha-1 receptors on smooth muscle cells. This action leads to the relaxation of muscle walls in blood vessels, a process called vasodilation, which lowers the resistance in the blood vessels and contributes to reduced blood pressure.


Q: Are there special considerations for children taking Alfadil?

Official prescribing information states that the use of Alfadil (doxazosin) in the pediatric population, which includes anyone under 18 years of age, is generally not recommended by regulatory agencies.


Q: What kind of studies have been done on Alfadil?

Research evidence includes short-term, randomized, placebo-controlled clinical trials (RCTs). These studies investigated the effects of Alfadil in adult populations with conditions such as high blood pressure (hypertension) and benign prostatic hyperplasia (BPH).


Q: Is Alfadil available over the counter in some countries?

Alfadil (doxazosin) is consistently classified as a prescription-only medicine by major global regulatory bodies. This means that access to the medicine requires a valid prescription from an authorized healthcare professional.


Q: How does Alfadil affect heart rate?

Studies on Alfadil (doxazosin) indicate that while it significantly affects blood pressure, it typically results in only a small change in overall cardiac output. Maximum reductions in blood pressure are associated with only a small increase in standing heart rate.


Q: Is Alfadil a diuretic?

Alfadil is officially classified as an alpha-adrenoreceptor antagonist. It does not belong to the drug class of diuretics, which primarily work by increasing the production of urine.


Q: What are the most common reasons patients stop taking Alfadil?

Clinical trial data indicate that discontinuation due to hypotensive or orthostatic symptoms, such as dizziness or lightheadedness, was a frequently reported reason for stopping therapy.


Q: Can people with kidney problems take Alfadil?

Official pharmacokinetic data shows that the majority of Alfadil is eliminated from the body via metabolism and fecal excretion, with only a small percentage (around 9%) eliminated in the urine. This suggests that kidney function is not the main way the drug is cleared from the body.


Q: Can Alfadil interact with common over-the-counter pain relievers?

Official safety information notes that non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen, may decrease the antihypertensive effects of Alfadil. This interaction is noted as pharmacodynamic antagonism.


Q: Does Alfadil affect cholesterol levels?

Some long-term studies referenced in regulatory documents have observed that, in addition to its blood pressure effects, Alfadil (doxazosin) has produced a modest reduction in total cholesterol, LDL-cholesterol, and triglyceride concentrations.

How should Alfadil be stored and disposed of?

Alfadil (Doxazosin) must be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The regulatory labeling permits brief temperature excursions between 15 C and 30 C.

Handling and Protection

The medicine must be stored in a closed container, away from excess moisture and direct light. It is essential to keep the product from freezing to maintain its stability and quality. Consistent with safety requirements, Alfadil must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired tablets should not be saved. Disposal of the contents and container must be carried out according to local regulations. To protect the environment, the medication should not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfadil found in:

A-Z Index: